Home › Compare › IOIOF vs ABBV
IOIOF yields 3.58% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, IOIOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IOIOF + ABBV for your $10,000?
IOI Corporation Berhad, an investment holding company, engages in the plantation business in Malaysia, Europe, North America, Asia, and internationally. The company operates through two segments, Plantation and Resource-Based Manufacturing. It cultivates oil palm, softwood timber, and rubber; refines and processes crude palm and palm kernel oils; and manufactures specialty oils and fats. The company also manufactures and exports fatty acids, soap noodles, glycerine, fatty esters, and other related products. In addition, it is involved in the commercialization of clonal ramets and biotechnology related research and development activities; provision of management and marketing services; production and supply of palm-based renewable energy; and trading of palm oil commodities. Further, the company engages in the property development, maintenance, and investment activities; issuance of exchangeable bonds and guaranteed notes; storage tanks rental activities; manufacture, registration, trading, and distribution of oleochemical products; and provision of bulk cargo warehousing services, as well as treasury management services and management consulting services. It owns oil palm planted area of 176,980 hectares. The company was formerly known as Industrial Oxygen Incorporated Sdn Bhd and changed its name to IOI Corporation Berhad in March 1995. IOI Corporation Berhad was incorporated in 1969 and is based in Putrajaya, Malaysia.
Full IOIOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.